Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBITDA (2020 - 2025)

Historic EBITDA for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$7.0 million.

  • Oncology Institute's EBITDA rose 4600.47% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.1 million, marking a year-over-year increase of 3854.72%. This contributed to the annual value of -$56.9 million for FY2024, which is 2323.27% up from last year.
  • As of Q3 2025, Oncology Institute's EBITDA stood at -$7.0 million, which was up 4600.47% from -$10.2 million recorded in Q2 2025.
  • Oncology Institute's 5-year EBITDA high stood at -$943000.0 for Q2 2021, and its period low was -$40.6 million during Q4 2021.
  • Over the past 5 years, Oncology Institute's median EBITDA value was -$14.3 million (recorded in 2023), while the average stood at -$14.9 million.
  • As far as peak fluctuations go, Oncology Institute's EBITDA plummeted by 180296.92% in 2022, and later soared by 4842.67% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's EBITDA stood at -$40.6 million in 2021, then skyrocketed by 39.32% to -$24.6 million in 2022, then surged by 41.18% to -$14.5 million in 2023, then grew by 24.06% to -$11.0 million in 2024, then surged by 35.9% to -$7.0 million in 2025.
  • Its EBITDA was -$7.0 million in Q3 2025, compared to -$10.2 million in Q2 2025 and -$8.9 million in Q1 2025.